Bivictrix Therapeutics Share Discussion Threads

[40 fathoms] 21/1/2024 01:46

2024 should be a very interesting year with the potential for a very significant share price reaction on any news related to partnership and/or BVX001 entering the clinic.

It seems that they don't need much more data to get BVX001 to the point where they will maximise the value for a partnering opportunity. The ADC areas is so hot at the moment if there is even half a chance that their approach might work they will have no problem finding a quality partner for BVX001.

[shortcpx] 20/7/2023 19:12

Turns out they were full of it. Tiny raise as well.

[jane deer] 19/7/2023 21:01

I see BVX doing a placing and subscription at 13p (below today's closing price of 15.9p). Directors and large shareholders were able to participate but ordinary shareholders are not - with no retail offer nor open offer. We see this story loads of times!!

But what is interesting is that towards the end of the 19 July RNS on the Proposed Fundraise on under the section "RIGHT TO TERMINATE UNDER THE PLACING AGREEMENT", Condition 3 has the following language which indicates that an Open Offer was also planned. At least someone forgot to delete the term "Open Offer" from the final version.

"if, amongst other things, there is a substantial change in any
national or international political, military, diplomatic, economic, financial
or market conditions which in the Joint Broker's opinion (acting in good faith
and after such consultation with the Company or the other Joint Broker as
shall be practicable in the circumstances) would have or be likely to have a
material and adverse effect on the Placing, the Open Offer or dealings in
Placing Shares in the secondary market or is of such magnitude to render the
Placing or the creation of a market in the Placing Shares temporarily or
permanently impracticable or inadvisable"

[40 fathoms] 18/7/2023 05:08

"Final data at day 28 showed that BVX001 induced highly statistically significant tumour regressions of 97% following administration of all eight scheduled doses of BVX001.

An animal group dosed with the vehicle only was used as a negative control in the study.

These final results build upon the interim preclinical efficacy data announced on June 19, 2023, which demonstrated highly statistically significant tumour regressions for BVX001 of up to 89% at day 18, following six out of the total eight planned doses of BVX001."

It really does not get much better than this, once we get clarity how will progress this towards the clinic this will fly.

[40 fathoms] 06/6/2023 08:07

"· BVX001 clinical candidate achieved statistically significant tumor regressions of up to 93% (p-value Acute Myeloid Leukemia (AML),

· Results further strengthen preclinical data package for BVX001, supporting progress towards the clinic"

Excellent ... cannot ask for more at this stage !

[40 fathoms] 02/4/2023 02:45

Excellent to see they are confident of being able to partner rather than coming back to the market for a CR. Given how hot the ADC market is currently it is exactly the right approach in my view.

Link below to the post results IR interview with the CEO

[40 fathoms] 17/12/2022 13:48

Latest update from CEO

[devonlad] 01/11/2022 16:37

bivictrix.com/wp-content/uploads/2022/10/041022_BVX-Corporate-Presentation-final.pdf

[small crow] 21/9/2022 14:33

Interesting.

[krowelet] 28/6/2022 10:15

Now gong south with most of the other Bio's, very little news since listing last August. We could do with a bit of progress news Tiff to keep us invested.

[shortcpx] 16/4/2022 22:46

Is there a link or copy of the report floating around? I know share price Angel had a table in their report of similar companies and a median valuation.

[shortcpx] 14/4/2022 00:43

https://www.proactiveinvestors.co.uk/companies/amp/news/979126

[40 fathoms] 12/4/2022 07:40

Panmure Gordon & Co initiated coverage of BiVictriX Therapeutics PLC with a buy.

PT set at 82 pence a 222% increase from yesterdays close.

[40 fathoms] 11/4/2022 00:37

Although a month or so out of date, I just realised that this had not been posted. Here Ms Thorn gives a few hints about the targets of the two new programs they are taking forward.

[40 fathoms] 07/3/2022 23:55

From the Chairman's statement

"The Board believes that the data generated in the short-term will be significant and attract pharma and mid-sized biotech companies interested in commercial partnerships and/or licensing. Although at an early stage our unique approach has already attracted the attention of third parties who wish to explore future partnering opportunities with us. Our aim is to position BiVictriX as a highly attractive business in the sector, and to provide maximum returns to our Shareholders."

[40 fathoms] 13/1/2022 10:36

A very large trade went through at 31.5p and in the blink of an eye we are at 35p. Despite the decent run up since the IPO this still remains very cheap. With a little bit of positive clinical news we could 2x or 3x from here and we would still not be mispriced.

[40 fathoms] 23/12/2021 08:22

Very nice to see Ms Thorn buy a good number of shares on market. The only thing that matters for this stock is does the science work and Ms Thorn is by far the best placed person to make a judgement in that regard.

[tony mahalski] 09/11/2021 09:59

2 US listed Bi Specific ADC targeting cos aren't more than a couple of years ahead and both valued at $US 1bn.BVX is £15m

[small crow] 08/11/2021 11:29

Some interest shown.

[krowelet] 31/10/2021 08:09

Not new, see holdings 13/8 but increasing, interesting.

[tony mahalski] 29/10/2021 22:02

New shareholder with 11%?

[small crow] 29/10/2021 15:21

Only in spite as my MTFB failure could have bought me a few....

[tony mahalski] 29/10/2021 14:35

Anyone following this?